FPR1 and Hypertension: The novel FPR agonist Cmpd17b has an antihypertensive effect and prevents impaired cardiovascular function and remodelling in hypertensive mice, supporting the development of pro-resolution FPR-based therapies to treat complications of systemic hypertension.